Skip to content

Vibrotactile Stimulation for Parkinson's Disease

Vibrotactile Stimulation for Parkinson's Disease

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07687732
Enrollment
12
Registered
2026-07-07
Start date
2023-08-23
Completion date
2025-08-16
Last updated
2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PARKINSON DISEASE (Disorder)

Keywords

Parkinson's disease, non-invasive stimulation, vibrotactile stimulation

Brief summary

Investigation on whether and how vibrotactile stimulation applied on the fingertips affects beta power in the subthalamic nucleus.

Detailed description

With a randomized order, two stimulation patterns are applied for one hour each on the fingertips of Parkinson's patients with deep brain stimulation, while periodically recording from subthalamic nucleus (STN) local field potentials (LFPs). The randomized vibrotactile stimulation (RVS) power is expected to reduce neuronal synchronization and LFP beta power. The All-on stimulation pattern is not expected to reduce neuronal synchronization and LFP beta power.

Interventions

Vibration patterns applied on the fingertips.

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* The population to be enrolled will be between 18 and 85 years of * Have a diagnosis of idiopathic Parkinson's disease, determined by a movement disorders neurologist at the CU Movement Disorders Center * Has undergone deep brain stimulation surgery at the University of Colorado hospital

Exclusion criteria

* have severe sensory abnormalities of the fingertips such as vibratory urticaria * Patients that cannot clearly communicate with staff and speak English * Patients that are on psychoactive or narcoleptic medications, medications that affect brain function or alter EEG recorded activity (i.e., anticonvulsants, ADHD, depression, or anxiety medication) * Participation in another drug, device, biologic, or intervention trial concurrently or within the preceding 30 days.

Design outcomes

Primary

MeasureTime frameDescription
Beta band powerAt baseline (pre-intervention) and after 30 min of intervention13-30 Hz frequency band

Secondary

MeasureTime frameDescription
MDS-UPDRS Part IIIAt baseline (pre-intervention) and 1-hour of interventionMovement disorder assessment for Parkinson's disease motor symptoms of the upper extremity. The scale is from 0 to 4 for the items in the MDS-UPDRS Part III, where 0 represents normal function (and 4 is worse).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026